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Summary
Multiple sclerosis is a demyelinating, neurodegenerative disease of the central nervous system, that affects the young 
adult and is associated with a high degree of disability. Physical and mental comorbidity and adverse health behaviors are 
common in patients with MS. Comorbidities and health behaviors are associated with adverse outcomes in MS and should 
be considered in the assessment and management of patients with MS.
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We have studied a group of 150 MS patients treated with immunomodulators inside the Romanian national MS 
treatment programme. The patients we analysed corresponded to the available literature in matters or number, age and 
sex. We searched for associated pathology and side effects of the treatment. After selecting and statistically analyzing the 
data we concluded that dyslipidemia was the most common comorbidity, followed by hyperglicemia and vertebral hernia. 
The presence or not of a comorbidity before the treatment does not relate to the EDSS score (p<0.05). Thus the presence 
or not of an associated pathology during 7 years of immunomodulatory treatment does not affect the patient’s EDSS 
score and disability. The most frequent side effects in our study were anemia, thrombocytopenia, raised liver enzymes, 
dyslipidemia, lymphocitopenia and neurtropenia. The anemia was a mild one, with no signifi cantly decrease haemoglobin 
and hematocrit levels. The same is observed with the liver enzymes, while the increase in SGOT and SGPT values are 
40% increase in comparison with the maximum accepted normal value. Summarizing the results of the side effects, it 
seems that as time of treatment rises, the side effects free patients decrease in actual number.
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Introduction
Multiple sclerosis is a chronic, infl ammatory 
demyelinating, neurodegenerative disease of 
the central nervous system, characterised by the 
destruction of myelin sheathsof the nerve fi bers with 
a relative sparing of the axons, the infi ltration of 
infl ammatory cells in a perivascular and paravenous 
distribution and the formation of plaques manily in 
the white matter in specifi c places. This neurological 
pathology affects 2,5 million young adults worldwide 
and in the USA 200 new patients are diagnosed with 
MS every week, according to the national MS society. 
In Romania, the incidence raised in the last years and 
because it is a disabilitating disease among the young 
population (20th and 30th decade) there are many 
studies involving MS. Besides the pathology and the 
disability that MS has, these patients come with other 
diseases and comorbidities, quite frequent also [1].
In a study conducted in France by Fromont et 
al, published in 2013,  among 22,087 patients, 653 
(3%) had a comorbidity status diagnosed at the same 
time as MS. Of these comorbidities, 86.8% could 
be grouped into fi ve main categories: psychiatric 
disease (40.2%), autoimmune disease (24.5%), 
cardiovascular disease (16.2%), cancer (12.2%), 
and metabolic disease (9.0%). Psychiatric disorders 
and diabetes were more frequent in MS patients 
than in the general population of the same age [2]. 
Canadian scientist Marrie and Hanwell researched 
the general health issues in MS and concluded that 
mental comorbidity is common in MS; depression 
has a lifetime prevalence of 50%, while anxiety has 
a lifetime prevalence of 36%. Physical comorbidity 
is also common, with the most frequently reported 
conditions including hyperlipidemia, hypertension, 
arthritis, irritable bowel syndrome, and chronic lung 
disease. Fracture risk is increased among patients 
with MS because of an increased risk of osteoporosis 
and propensity for falls. Vitamin D insuffi ciency is 
common and may contribute to increased fracture 
risk and increased disease activity. Comorbidities 
and smoking are associated with diagnostic delays, 
increased disability progression, lower health-related 
quality of life, and lower adherence to treatment [3].
There are many theories about the ethiology of 
MS but none proved to be the certain one. Thus the 
treatment for MS is not one curative, but instead trying 
to modulate the immune response. According to major 
populational studies so far the immunomodulatory 
treatment proved to modify the natural evolution 
of this disease, by lowering the relapse rate and the 
disability after a relapse, prolonging in this way the 
handicap free duration and quality of life for MS 
patients. But, this treatment comes with side effects, 
mostly manageable [4]. 
The immunomodulatory treatment for MS 
is composed by interferons, glatiramer acetate 
and natalizumab. The interferons (IFN) are anti-
infl ammatory cytokines and they are one of the body’s 
earliest responses to a viral infection. Additionally, 
they present antineoplastic and immunomodulatory 
activity, by regulation of cell growth and proliferation, 
and modulation of immune responses [5]. Interferons 
are classifi ed according to the cell type from which 
they were initially delivered. The MS therapy uses 
INF β 1a and 1b under different commercial names. 
The adverse effects of IFN administration are many. 
The most frequent one is the fl u like syndrome that 
occurs in 50% of the treated patients. This includes 
fever, chills, weakness, fatigue, myalgia and arthralgia. 
The fl u like syndrome may follow each injection, 
but it does not last more than 24 hours and it occurs 
mainly during the fi rst weeks or months of treatment 
and after many repeated doses the drug becomes 
well tolerated. In some few cases, the symptoms 
persist and the discontinuation of therapy should be 
considered. Another side effect are the reactions at the 
injection sites, in 90% of patients, like pain, redness, 
induration and rarely, skin necrosis. Other side effects 
include headache, dizziness, agitation, insomnia and 
anxiety. Depression is common, with rare suicidal 
behaviour. Myelosupression occurs frequently and 
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may be dose limited. Gastrointestinal symptoms like 
nausea, vomiting, diarrhoea and anorexia appear often. 
Biological side effects include increased liver enzymes, 
low leucocytes, renal toxicity, proteinuria [6, 7].
Glatiramer acetate is a synthetic mixture of 
random acetate salts of polypeptides, which are 
composed of four naturally amino acids L-alanine, 
L-glutamic acid, L-lysine and L-tyrosine. Practically 
glatiramer acetate is a myelin basic protein fragment 
(MBP) and in MS was designed to inhibit the T-cell 
response to MBP, and also to inhibit the possible 
autoantigenes and cross-react with MBP. The side 
effects of glatiramer acetate are minimal and it is 
generally well tolerated. The primary side effect is 
the local injection site reactions that occur in 90% of 
patients. They consist of erythema with or without 
induration, brief pain, subcutaneous lipoatrophy, 
but never skin necrosis. Another self-limiting post-
injection reaction with fl ushing, sweating, throat 
constriction, chest tightness, dyspnea, anxiety and 
palpitation that last up to 30 minutes are reported in 
almost 30% patients. Other experienced side effects 
include vasodilatation, asthenia, infection, pain, 
nausea, arthralgia and hypertonia [8].  The difference 
between IFN and glatiramer acetate is that some 
patients treated with IFN can develop neutralising 
antibodies to IFN and therefore the drug will not be 
able to maintain its functions. Also both therapies 
are considered to be teratogenic and should not be 
administered during pregnancy [9]. 
Natalizumab is a monoclonal antibody, an 
antagonist of the a4 integrin which is expressed on 
the surface of the infl ammatory lymphocytes and 
monocytes. By binding to this protein, natalizumab 
increases the circulating pre-B and B-cells, and 
therefore the CD19+ mature B cells, decreasing in 
this way the manifestations of disease activity and 
infl ammation [10]. More precisely, it was observed 
a 66% reduction of relapses, while 76% of patients 
were relapse free, the MRI lesions decreased by 92% 
and the number of T2 lesions was reduced by 80% 
according to the AFFIRM study [11]. Among the 
adverse effects of natalizumab is the production of 
antibodies against it. In the AFFIRM trial, antibodies 
were detected in 8% of patients at the beginning 
of treatment and in 88% of patients after the fi rst 
12 weeks of treatment. Other side effects include 
headache, nausea, urticaria and low leucocytes 
count. The most important adverse effect in positive 
JC virus patients is the developing of the multifocal 
leukoencephalopathy, which untreated leads to death. 
The risk of developing this pathology is estimated to 
be one person from every 1000 patients treated for an 
average of 17.9 months [12]. 
Material and method
The main goal for this study was to observe the 
adverse effects of the immunomodulatory treatment 
on MS patients, but also to register the associative 
pathology they presented. The 150 patients included 
in this study were in the evidence of the Neurology 
Clinic in the Clinical Rehabilitation Hospital and 
also treated inside the Romanian National MS 
Treatment Programme. The criteria that was defi ned 
for the selection of patients to enter this study was the 
following:
- Age between 18 and 60 years old
- Confi rmed MS diagnosis
- Relapsing remitting or secondary progressive 
form of MS 
- Agreement from patients that their personal 
data and the results of this study could be used for 
further observations and publications.
The method used was clinical examination, 
together with the detailed medical and family history, 
EDSS score determination and biological (blood) 
analyses. The medical history was necessary in order 
to determine the comorbidities of the patients, the 
life style and risk factors. The clinical examination 
was performed to establish the EDSS score and to 
take blood for the biological analyses. All data were 
analyzed in SPSS.20 statistical programme. 
Results
We have studied 150 patients from the records of 
the Neurology Clinic inside the Clinical Rehabilitation 
Hospital Iasi, among which 38 were receiving Avonex 
(IFN β-1a), 41 patients were treated with Rebif (IFN 
β-1a), 34 with Copaxone (glatiramer acetate) and 37 
with Betaferon (IFN β-1b). 
Figure 1. Distribution of the immunomodulatory treatment
The associated pathology (comorbidities) was 
studied in order to  observe whether other diseases 
than MS may infl uence the treatment outcome or 
the progression of the disease. The following table 
consists of the associated pathology that was met 
in our patients during the years of treatment. It is 
demonstrated that total sample, the actual frequencies 
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of the cases and the percentages of every case. As we 
notice from a total sample of 150 patients only 71 had 
no associated pathology (47,3%). This means that one 
out of two patients had an associated pathology. On 
the other hand the 25,3% of the patients was confi rmed 
to have dyslipidemia and 8,7% hyperglycemia.
Table 1 
Distribution of the comorbidities in our study





No comorbidities 71 47,3%
Dyslipidemia 38 25,3%
Hyperglycemia 13 8,7%
Vertebral hernia 9 6%
Arachnoid cyst 6 4%
Iron defi ciency anemia 6 4%
Hypertension 5 3,3%
Obesity 3 2%
Undefi ned neoplasia 3 2%
Hepatitis B 3 2%
Thyreoidopathy 2 1,3%
Osteoporosis 2 1,3%
Other (ulcer, osteonecrosis, venous 
insuffi ciency, Raynaud syndrome, 
arythmias, tuberculosis, uterine 
fi broma, Lyme disease)
15 10%
Considering the tabel above we can conclude 
that dyslipidemia is the most common comorbidity, 
followed by hyperglicemia and vertebral hernia. 
Proceeding with the analysis we will examine if the 
associated pathology infl uenced the EDSS score. 
As we will notice in the following statistical tables 
the estimated value of the EDSS score before the 
treatment for those patients with associated pathology 
is 2.14 and for those with no associated pathology 
2.24. The deviation is estimated at 0.09, which is not 
considered statistically signifi cant. Thus the presence 
or not of a comorbidity before the treatment does not 
relate to the EDSS score (p<0.05).
Table 2 









EDSS   yes 71 2,1479 .93787 .11130
                 No 79 2,2405 1,08489 .12206
In the following tables we have examined the 
infl uence of associated pathology on the EDSS 
score after a period of 7 years of immunomodulatory 
treatment. As we noticed the estimated mean value of 
the EDSS for those patients with associated pathology 
is 3.00 and for those with no associated pathology is 
2.4. The deviation is estimated at 0.59 which is not 
considered statistically signifi cant. Thus the presence 
or not of an associated pathology during 7 years of 
immunomodulatory treatment does not affect the 
patient’s EDSS score and disability.
Table 3 










EDSS 7y       
yes
7 3,000 1,32288 .50000
No 11 2,4091 1,48017 .44629
As for the side effects of the immunomodulatory 
treatment, fi rst we analysed the patients whose period 
Figure 2. Side effects of 7 years treated patients.
170 Buletinul AȘM
of treatment lasted 7 years. The fi gure below depicts 
the fact that the side effects fl uctuated during the 
whole period. There are periods with a few cases 
and other periods with much more side effects cases. 
Beyond these, the total cases of patients with no side 
effects decrease signifi cantly during the whole period. 
More specifi cally, at the beginning of the treatment 
there were 8 patients with no side effects, when in the 
end there were only four with no side effects.
Secondly, we will deal with those patients whose 
period of treatment lasted 6 years. Specluating 
the fi gure below is obvious that the side effects 
fl uctuate during the whole period, but there seems to 
be an increase of the side effects such as decreased 
neutrophils levels and liver enzimes. Beyonf this, 
the total cases of patients with no side effects have 
a decrease during the period of the third to the sixth 
year.
Finally, we will deal with those patients whose 
period of treatment lasted 3 years. Examining the 
fi gure below is obvious that the side effects are 
mostly stable. The total cases of patients with no side 
effects decreased from 12 to 10. Because of the small 
period of time (3 years) we cannot exclude reliable 
and unbiased results, but all side effects seem to be 
stable.
Discutions
First of all, after the primary statistical analysis 
we concluded that our group of patients was an 
omogenous one and that it refl ected the literature in 
matters of age and sex. Although we have examined a 
lot of parameters in this group, in this article we will 
refer to associated pathology and to the side effects 
of the immunomodulatory treatment. Until the fi rst 
year of treatment the EDSS score seemed to be quite 
stable. However, with slight fl uctuations the EDSS 
score started to mildly increase up to 2,63 in the 
seventh year of treatment, results that were similar 
to the literature. The statistical signifi cance is not 
important and thus, we presume that the EDSS score 
remained stable during all years of treatment with a 
slight tendency of increasing, but did not infl uenced 
the associated pathology or the side effects of the 
treatment. Also, the duration of the treatment did 
not infl uenced the EDSS score in any administrated 
medication of this study.
Concerning the associated pathology that 
was observed in our patients during the years of 
treatment, it is documented that 53,7% of the total 
sample presented an additional pathology. The most 
frequent of all was dyslipidemia, which reached the 
percentage of 25,3%, followed by hyperglycemia 
Figure 3. Side effects for 6 years treated patients.
Figure 4. Side effects for 3 years treated patients.
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(8,7%). Vertebral hernias  in cervical or lumbar 
spinal column, associated with laminectomies or 
spondylofussion was found in 6% of our patients. 
Further, 4% of them were suffering from arachnoid 
cyst and iron defi ciency anemia. The one in 6 patients 
with arachnoid cysts developed epileptic convulsions 
during the fourth year of treatment. However, his 
EDSS score or his annual relapse rate was not 
infl uenced by the underlying disease. Hereditary 
diseases like Gilbert syndrome, Charcot Marie Tooth 
Neuropathy and Venous Insuffi ciency were also 
recorded, as well as idiopathic diseases like Raynaud 
syndrome. Finally, there were also one case of 
infection with H1N1 virus, Hepatitis B, Lyme disease 
and tuberculosis.
Another interesting point of the comorbidities 
analysis is the metabolic diseases. As it is already 
mentioned, 25,3% of the patients developed 
dyslipidemia and 8,7% hyperglycemia. Additionally, 
three patients of our group were obese and on the 
other hand another two women lost a lot of kilos 
during the fi rst year of treatment. However, we cannot 
correlate a specifi c medication with the metabolic 
syndrome, since approximately the actual numbers 
of medication and dyslipidemia or hyperglycemia are 
the same. After detailed analysis of the EDSS score 
in relation to the associated pathology, it is concluded 
that the EDSS score is not infl uenced by the existence 
of other than MS disease, either hereditary or 
idiopathic, or metabolic, neoplasias, vascular disease 
and infections.
As regard to side effects, the group of patients 
with seven years of treatment, does not present side 
effects in the fi rst year of treatment. However, as 
time goes by, side effect’s percentage rise. Anemia, 
raised liver enzymes and dyslipidemia are the most 
common side effects. In patients who were treated 
for 6 years, the side effects appearance seem to 
rise over time. Adverse events like decreased 
neurtrophilia and increased liver enzymes are most 
often met, followed by anemia and dyslipidemia. In 
the 3 years treated group of patients, the side effect 
free number of cases seems to decrease through the 
years. Thrombocytopenia and raised liver enzymes 
are the most commonly met pathological side effects. 
However, it is estimated that in this specifi c group of 
patients the side effects remain stable. 
Summarizing the results of the side effects, it 
seems that as time of treatment rises, the side effects 
free patients decrease in actual number. The most 
frequent side effects are anemia, thrombocytopenia, 
raised liver enzymes, dyslipidemia, lymphocitopenia 
and neurtropenia. As to anemia, it is a mild one, with 
no signifi cantly decrease haemoglobin and hematocrit 
levels. The same is observed with the liver enzymes, 
while the increase in SGOT and SGPT values are 40% 
increase in comparison with the maximum accepted 
normal value.     
Conclusions
Multiple sclerosis is a chronic, infl ammatory 
demyelinating, neurodegenerative disease of the 
central nervous system, that affects the young adult 
and is associated with a high degree of disability if 
not treated. There is no curable treatment but the 
immunomodulatory one is aimed in decreasing 
the relapse rate and the disability following the 
relapse. Physical and mental comorbidity and 
adverse health behaviors are common in patients 
with MS. Comorbidities and health behaviors are 
associated with adverse outcomes in MS and should 
be considered in the assessment and management of 
patients with MS.
The group of patients we analysed corresponded 
to the available literature in matters or number, age 
and sex. We concluded that dyslipidemia was the most 
common comorbidity, followed by hyperglicemia and 
vertebral hernia. The presence or not of a comorbidity 
before the treatment does not relate to the EDSS score 
(p<0.05). Thus the presence or not of an associated 
pathology during 7 years of immunomodulatory 
treatment does not affect the patient’s EDSS score 
and disability.
The most frequent side effects in our study were 
anemia, thrombocytopenia, raised liver enzymes, 
dyslipidemia, lymphocitopenia and neurtropenia. 
The anemia was a mild one, with no signifi cantly 
decrease haemoglobin and hematocrit levels. The 
same is observed with the liver enzymes, while the 
increase in SGOT and SGPT values are 40% increase 
in comparison with the maximum accepted normal 
value. Summarizing the results of the side effects, it 
seems that as time of treatment rises, the side effects 
free patients decrease in actual number.
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